注册 English

Design, synthesis, characterization, cytotoxic and structure activity relationships of novel Ru(II) complexes

Sreekanth Thota ,  Srujana Vallala ,  Rajeshwar Yerra ,  Eliezer J. Barreiro

downloadPDF
Citation:  Sreekanth Thota, Srujana Vallala, Rajeshwar Yerra, Eliezer J. Barreiro. Design, synthesis, characterization, cytotoxic and structure activity relationships of novel Ru(II) complexes[J]. Chinese Chemical Letters, 2015, 26(6): 721-726. doi: 10.1016/j.cclet.2015.03.011 shu

Design, synthesis, characterization, cytotoxic and structure activity relationships of novel Ru(II) complexes

    • 通讯作者: Sreekanth Thota,
  • 基金项目:

    Technological Development (CNPq) (CNPq)

    vel Superior (CAPES) (CAPES)

    Oswaldo Cruz Foundation (Fiocruz)  (Fiocruz)

摘要: Platinum containing compounds have shown antineoplastic potential, but their clinical applications have been limited by high toxicity. Ruthenium containing complexes have long been known to be well suited for biological applications, and have long been utilized as replacements to popular platinum based-drugs. Here, we report a novel series of ruthenium(II) arene compounds bearing thiosemicarbazone and isonicotinylhydrazone ligands with potent anticancer activity their structure activity relationships and apoptosis was studied. The cytotoxic activity of the new ruthenium(II) arene compounds has been evaluated in several cell lines (Molt 4/C8, L1210, CEM, HL60 and BEL7402). Among them, ten complexes were found to be excellent in vitro growth inhibitory activity against various cell lines with IC50 in the sub-micromolar range.

English

  • 

    1. [1] M. Patra, G. Gasser, Organometallic compounds: an opportunity for chemical biology? ChemBioChem 13 (2012) 1232-1252.[1] M. Patra, G. Gasser, Organometallic compounds: an opportunity for chemical biology? ChemBioChem 13 (2012) 1232-1252.

    2. [2] N.P. Barry, P.J. Sadler, Challenges for metals in medicine: how nanotechnology may help to shape the future, ACS Nano 7 (2013) 5654-5659.[2] N.P. Barry, P.J. Sadler, Challenges for metals in medicine: how nanotechnology may help to shape the future, ACS Nano 7 (2013) 5654-5659.

    3. [3] C.M. Clavel, E. Păunescu, P. Nowak-Sliwinska, et al., Discovery of a highly tumorselective organometallic ruthenium(II)-arene complex, J. Med. Chem. 57 (2014) 3546-3558.[3] C.M. Clavel, E. Păunescu, P. Nowak-Sliwinska, et al., Discovery of a highly tumorselective organometallic ruthenium(II)-arene complex, J. Med. Chem. 57 (2014) 3546-3558.

    4. [4] C.G. Hartinger, M.A. Jakupec, S. Zorbas-Seifried, et al., KP1019, a new redox-active anticancer agent-preclinical development and results of a clinical phase I study in tumor patients, Chem. Biodivers. 5 (2008) 2140-2155.[4] C.G. Hartinger, M.A. Jakupec, S. Zorbas-Seifried, et al., KP1019, a new redox-active anticancer agent-preclinical development and results of a clinical phase I study in tumor patients, Chem. Biodivers. 5 (2008) 2140-2155.

    5. [5] I. Romero-Canelón, L. Salassa, P.J. Sadler, The contrasting activity of iodido versus chlorido ruthenium and osmium arene azo-and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway, J. Med. Chem. 56 (2013) 1291-1300.[5] I. Romero-Canelón, L. Salassa, P.J. Sadler, The contrasting activity of iodido versus chlorido ruthenium and osmium arene azo-and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway, J. Med. Chem. 56 (2013) 1291-1300.

    6. [6] G.S. Smith, B. Therrien, Targeted and multifunctional arene ruthenium chemotherapeutics, Dalton Trans. 40 (2011) 10793-10800.[6] G.S. Smith, B. Therrien, Targeted and multifunctional arene ruthenium chemotherapeutics, Dalton Trans. 40 (2011) 10793-10800.

    7. [7] D.S. Kalinowski, P. Quach, D.R. Richardson, Thiosemicarbazones: the new wave in cancer treatment, Future Med. Chem. 1 (2009) 1143-1151.[7] D.S. Kalinowski, P. Quach, D.R. Richardson, Thiosemicarbazones: the new wave in cancer treatment, Future Med. Chem. 1 (2009) 1143-1151.

    8. [8] D.R. Richardson, D.S. Kalinowski, V. Richardson, et al., 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity, J. Med. Chem. 52 (2009) 1459-1470.[8] D.R. Richardson, D.S. Kalinowski, V. Richardson, et al., 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity, J. Med. Chem. 52 (2009) 1459-1470.

    9. [9] B.M. Zeglis, V. Divilov, J.S. Lewis, Role of metalation in the topoisomerase IIa inhibition and antiproliferation activity of a series of α-heterocyclic-N4-substituted thiosemicarbazones and their Cu(II) complexes, J. Med. Chem. 54 (2011) 2391-2398.[9] B.M. Zeglis, V. Divilov, J.S. Lewis, Role of metalation in the topoisomerase IIa inhibition and antiproliferation activity of a series of α-heterocyclic-N4-substituted thiosemicarbazones and their Cu(II) complexes, J. Med. Chem. 54 (2011) 2391-2398.

    10. [10] J. Liu, W.J. Zhen, S. Shi, et al., Synthesis, antitumor activity and structure-activity relationships of a series of Ru(II) complexes, J. Inorg. Biochem. 102 (2008) 193-202.[10] J. Liu, W.J. Zhen, S. Shi, et al., Synthesis, antitumor activity and structure-activity relationships of a series of Ru(II) complexes, J. Inorg. Biochem. 102 (2008) 193-202.

    11. [11] U. Schatzschneider, J. Niesel, I. Ott, et al., Cellular uptake, cytotoxicity, and metabolic profiling of human cancer cells treated with ruthenium(II) polypyridyl complexes [Ru(bpy)2(N-N)]Cl2 with N-N = bpy, phen, dpq, dppz, and dppn, ChemMedChem 3 (2008) 1104-1109.[11] U. Schatzschneider, J. Niesel, I. Ott, et al., Cellular uptake, cytotoxicity, and metabolic profiling of human cancer cells treated with ruthenium(II) polypyridyl complexes [Ru(bpy)2(N-N)]Cl2 with N-N = bpy, phen, dpq, dppz, and dppn, ChemMedChem 3 (2008) 1104-1109.

    12. [12] Y.J. Liu, C.H. Zeng, H.L. Huang, L.X. He, F.H. Wu, Synthesis, DNA-binding, photocleavage, cytotoxicity and antioxidant activity of ruthenium(II) polypyridyl complexes, Eur. J. Med. Chem. 45 (2010) 564-571.[12] Y.J. Liu, C.H. Zeng, H.L. Huang, L.X. He, F.H. Wu, Synthesis, DNA-binding, photocleavage, cytotoxicity and antioxidant activity of ruthenium(II) polypyridyl complexes, Eur. J. Med. Chem. 45 (2010) 564-571.

    13. [13] C.M. Kepert, G.B. Decon, N. Sahely, et al., Synthesis of heteroleptic bis(diimine)-carbonylchlororuthenium(II) complexes from photodecarbonylated precursors, Inorg. Chem. 43 (2004) 2818-2827.[13] C.M. Kepert, G.B. Decon, N. Sahely, et al., Synthesis of heteroleptic bis(diimine)-carbonylchlororuthenium(II) complexes from photodecarbonylated precursors, Inorg. Chem. 43 (2004) 2818-2827.

    14. [14] C.P. Tan, J. Liu, H. Li, et al., Differences in structure, physiological stability, electrochemistry, cytotoxicity, DNA and protein binding properties between two Ru(III) complexes, J. Inorg. Biochem. 102 (2008) 347-358.[14] C.P. Tan, J. Liu, H. Li, et al., Differences in structure, physiological stability, electrochemistry, cytotoxicity, DNA and protein binding properties between two Ru(III) complexes, J. Inorg. Biochem. 102 (2008) 347-358.

    15. [15] S.S. Karki, S. Thota, A. Katiyar, et al., Synthesis, characterization and cytotoxic activity of some Ru(II) complexes, Turk. J. Pharm. Sci. 8 (2011) 207-218.[15] S.S. Karki, S. Thota, A. Katiyar, et al., Synthesis, characterization and cytotoxic activity of some Ru(II) complexes, Turk. J. Pharm. Sci. 8 (2011) 207-218.

    16. [16] C.P. Tan, S. Lai, S.H. Wu, et al., Nuclear permeable ruthenium(II) b-carboline complexes induce autophagy to antagonize mitochondrial-mediated apoptosis, J. Med. Chem. 53 (2010) 7613-7624.[16] C.P. Tan, S. Lai, S.H. Wu, et al., Nuclear permeable ruthenium(II) b-carboline complexes induce autophagy to antagonize mitochondrial-mediated apoptosis, J. Med. Chem. 53 (2010) 7613-7624.

    17. [17] F. Caruso, E. Monti, J. Matthews, et al., Synthesis, characterization, and antitumor activity of water-soluble (arene)ruthenium(II) derivatives of 1,3-dimethyl-4-acylpyrazolon-5-ato ligands. First example of Ru(arene)(ligand) antitumor species involving simultaneous Ru-N7(guanine) bonding and ligand intercalation to DNA, Inorg. Chem. 53 (2014) 3668-3677.[17] F. Caruso, E. Monti, J. Matthews, et al., Synthesis, characterization, and antitumor activity of water-soluble (arene)ruthenium(II) derivatives of 1,3-dimethyl-4-acylpyrazolon-5-ato ligands. First example of Ru(arene)(ligand) antitumor species involving simultaneous Ru-N7(guanine) bonding and ligand intercalation to DNA, Inorg. Chem. 53 (2014) 3668-3677.

    18. [18] S. Thota, M. Imran, M. Udugula, et al., Synthesis, spectroscopic characterization and in vitro antitumor activities of some novel mononuclear Ru(II) complexes, Chin. Chem. Lett. 23 (2012) 466-469.[18] S. Thota, M. Imran, M. Udugula, et al., Synthesis, spectroscopic characterization and in vitro antitumor activities of some novel mononuclear Ru(II) complexes, Chin. Chem. Lett. 23 (2012) 466-469.

    19. [19] S. Thota, S.S. Karki, K.N. Jayaveera, J. Balzarini, E. De Clercq, Synthesis, characterization, antitumor, and cytotoxic activity of mononuclear Ru(II) complexes, J. Coord. Chem. 63 (2010) 4332-4346.[19] S. Thota, S.S. Karki, K.N. Jayaveera, J. Balzarini, E. De Clercq, Synthesis, characterization, antitumor, and cytotoxic activity of mononuclear Ru(II) complexes, J. Coord. Chem. 63 (2010) 4332-4346.

    20. [20] S. Thota, S.S. Karki, K.N. Jayaveera, J. Balzarini, E. De Clercq, Synthesis, antineoplastic and cytotoxic activities of some mononuclear Ru(II) complexes, J. Enzyme Inhib. Med. Chem. 25 (2010) 513-519.[20] S. Thota, S.S. Karki, K.N. Jayaveera, J. Balzarini, E. De Clercq, Synthesis, antineoplastic and cytotoxic activities of some mononuclear Ru(II) complexes, J. Enzyme Inhib. Med. Chem. 25 (2010) 513-519.

    21. [21] S.S. Karki, S. Thota, S.Y. Darj, J. Balzarini, E. De Clercq, Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds, Bioorg. Med. Chem. 15 (2007) 6632-6641.[21] S.S. Karki, S. Thota, S.Y. Darj, J. Balzarini, E. De Clercq, Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds, Bioorg. Med. Chem. 15 (2007) 6632-6641.

    22. [22] J.A. Hickman, Apoptosis induced by anticancer drugs, Cancer Metastasis Rev. 11 (1992) 121-139.[22] J.A. Hickman, Apoptosis induced by anticancer drugs, Cancer Metastasis Rev. 11 (1992) 121-139.

    23. [23] K. Gangarapu, S. Manda, S. Thota, et al., Microwave assisted synthesis, characterization of some new isatin and thiophene derivatives as cytotoxic and chemopreventive agents, Lett. Drug Des. Discov. 9 (2012) 934-941.[23] K. Gangarapu, S. Manda, S. Thota, et al., Microwave assisted synthesis, characterization of some new isatin and thiophene derivatives as cytotoxic and chemopreventive agents, Lett. Drug Des. Discov. 9 (2012) 934-941.

  • 加载中
WeChat 扫一扫看文章
计量
  • PDF下载量:  0
  • 文章访问数:  1227
  • HTML全文浏览量:  30
文章相关
  • 发布日期:  2015-03-19
  • 收稿日期:  2014-12-12
  • 网络出版日期:  2015-02-27
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

/

返回文章

All Rights Reserved by the Chinese Chemical Society   中国化学会 版权所有 京ICP备05002797号

本系统由北京仁和汇智信息技术有限公司开发    技术支持: info@rhhz.net